Nefrocenter Dialgest s.r.l.

NefroCenter is the first Italian private group specialized in the field of nephrology, dialysis and diabetology. It is also present in the fields of cardiology, neurology, rehabilitation, diagnostic imaging and laboratory, molecular biology and genetics. The services provided, provided in agreement with the NHS, are taken care of by a team of specialists with cutting-edge technologies and guarantee the patient efficient and high quality assistance.

In 2016 the NefroCenter group also started the first important research projects in collaboration with the Federico II University and the University of Campania "Luigi Vanvitelli" and with the La Sapienza University of Rome, founding NefroCenter Research.
At the end of 2018, with the acquisition of the pharmaceutical industry, LA.FA.RE srl enters the pharma sector.

In 2023 the Nefrocenter group will take over the Rome American Hospital (RAH) and the RSA Longoni. The health facilities, both in the city of Rome, have a total of 292 beds, of which: 160 at the RAH (including 10 intensive care places and coronary unit), 24 dialysis places (accredited with the NHS), and 108 at the RSA of which 18 semi-residential places and Integrated Home Care (ADI) all accredited with the NHS.